We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

107 hedge funds and large institutions have $1.08B invested in Avidity Biosciences in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 26 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

54% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 26

0.47% less ownership

Funds ownership: 97.32% → 96.85% (-0.47%)

1% less capital invested

Capital invested by funds: $1.09B → $1.08B (-$14.2M)

4% less funds holding

Funds holding: 111 → 107 (-4)

19% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 16

71% less call options, than puts

Call options by funds: $2K | Put options by funds: $7K

Holders
107
Holders Change
-4
Holders Change %
-3.6%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
13
Increased
40
Reduced
26
Closed
16
Calls
$2K
Puts
$7K
Net Calls
-$5K
Net Calls Change
-$209K

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$15.3M
2
GPP
Great Point Partners
Connecticut
+$11.9M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$9.9M
4
Marshall Wace
Marshall Wace
United Kingdom
+$5.96M
5
APM
Avidity Partners Management
Texas
+$4.06M

Top Sellers

1
PA
Perceptive Advisors
New York
-$21.8M
2
Goldman Sachs
Goldman Sachs
New York
-$5.59M
3
Deutsche Bank
Deutsche Bank
Germany
-$5.26M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.95M
5
5VM
5AM Venture Management
California
-$3.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$184M +$15.3M +641,196 +9%
RI
2
RTW Investments
New York
$114M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$89.8M -$1.36M -57,143 -1%
BlackRock
4
BlackRock
New York
$78.4M +$2.02M +84,704 +3%
EC
5
EcoR1 Capital
California
$65.6M – – –
Federated Hermes
6
Federated Hermes
Pennsylvania
$58.8M -$33.4K -1,400 -0.1%
CAM
7
Cormorant Asset Management
Massachusetts
$47.8M -$3.58M -150,000 -7%
Vanguard Group
8
Vanguard Group
Pennsylvania
$47.6M +$1.46M +60,959 +3%
APM
9
Avidity Partners Management
Texas
$43.1M +$4.06M +170,000 +10%
State Street
10
State Street
Massachusetts
$33.2M -$755K -31,601 -2%
ACA
11
Avoro Capital Advisors
New York
$29.2M +$1.91M +80,000 +7%
BC
12
Boxer Capital
California
$26.7M – – –
Wellington Management Group
13
Wellington Management Group
Massachusetts
$24.3M +$9.9M +414,457 +68%
DTC
14
Deep Track Capital
Connecticut
$23.8M +$23.9M +1,000,000 New
ACM
15
Alethea Capital Management
Washington
$21.1M -$431K -18,030 -2%
Alkeon Capital Management
16
Alkeon Capital Management
New York
$20.4M -$357K -14,960 -2%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$17M -$598K -25,025 -3%
GPP
18
Great Point Partners
Connecticut
$11.9M +$11.9M +500,000 New
OCA
19
Octagon Capital Advisors
New York
$10.6M – – –
RCM
20
RA Capital Management
Massachusetts
$10.1M – – –
5VM
21
5AM Venture Management
California
$9.28M -$3.94M -165,000 -30%
Northern Trust
22
Northern Trust
Illinois
$9.01M +$573K +24,011 +7%
Charles Schwab
23
Charles Schwab
California
$6.93M +$191K +7,990 +3%
Marshall Wace
24
Marshall Wace
United Kingdom
$6.29M +$5.96M +249,755 +1,684%
AG
25
Artal Group
Luxembourg
$5.94M +$2.57M +107,500 +75%
1
2 3 4 5

RNAM Hedge Fund Activity: Q4 2021 in Review

107 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q4 2021, worth a combined $1.08B — down 1.3% from $1.09B a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of RNAM and 13 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 40 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $15.3M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $21.8M sold.

  • 107 institutional investors held Avidity Biosciences (RNAM) as of Q4 2021, down from 111 in Q3 2021.
  • Funds reported $1.08B of Avidity Biosciences stock for Q4 2021, down 1.3% quarter-over-quarter.
  • 13 funds opened new Avidity Biosciences positions in Q4 2021 and 16 closed out, a net change of -3 holders.
  • The largest Avidity Biosciences buyer in Q4 2021 was T. Rowe Price Associates, an estimated $15.3M added.
  • The largest Avidity Biosciences seller in Q4 2021 was Perceptive Advisors, an estimated $21.8M sold.

Based on aggregated 13F filings for Q4 2021.